Implementing strategies, such as dose rounding, can offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent study of practices participating in the Oncology Care Model.
Dose rounding of biological anti-neoplastic agents, such as reference bevacizumab (Avastin) and its FDA-approved biosimilars (n = 4), was shown to offset the impact of drug waste and reduce the total cost of care for value-based programs, according to a recent analysis of Oncology Care Model (OCM) practices.
The results were presented at the American Society of Clinical Oncology Annual Meeting, which took place from June 2 to June 6, 2023, in Chicago, Illinois.
The OCM was a 6-year long Medicare value-based care program that offered practices rewards for decreasing total cost of care (TCOC) compared with a benchmark price without impacting the ability to maintain high-quality cancer care. Drug waste from partially used single-dose vials of expensive biologics is considered to be a leading contributor to TCOC expenditures for payers.
Dose rounding (DR), whereby doses of anticancer treatments are rounded up or down between 5% and 10% of the ordered dose in line with recommendations from Hematology Oncology Pharmacists Association and endorsed by the National Comprehensive Cancer Network, is a common approach to mitigate the impact of drug waste.
In 2018, many OCM practices adopted a DR program for biologic agents as a strategy to reduce drug waste and TCOC. However, whether the strategy worked remained to be seen. The researchers assessed claims data for 14 practices in The US Oncology Network participating in the OCM. The data included drug administration data for reference bevacizumab and bevacizumab biosimilars (Vegzelma, Mvasi, Zirabev, and Alymsys) to evaluate drug waste, total dose, TCOC, DR, and the financial impact of drug waste reduction on TCOC from 2017 to 2021.
Prior to implementing DR, on average 5.3% (range, 4.6% to 5.5%) of the total dose of bevacizumab products was wasted, with about 25% of bevacizumab administrations having wasted over 10% of the total dose.
A DR initiative led to a reduction of waste for 30% of the total number of bevacizumab administration across all 14 practices. As a result of DR, bevacizumab drug waste decreased by 55% to an average 2.5% (range, –2.3% to 2.7%) of the total dose in 2021. The decreased waste resulted in TCOC reduction of about $100 per member episode per month (0.97% of TCOC) for episodes with a bevacizumab administration.
The highest waste reduction was seen in situations where the patient was receiving bevacizumab as a treatment for gastrointestinal cancer (colon, rectal, anal, gastroesophageal, or pancreatic) compared with other cancer types (lung, brain, ovarian, etc). Also, there was about a 50% reduction in cases where bevacizumab drug waste were over 10% of the total dose.
The authors noted that a similar DR approach could be adopted for other high-cost originator and biosimilar biologic agents where drug waste results from partial use of single dose vials.
Reference
Indurlal P, Alam N, Garey JS, Wilfong LS. Dose rounding bevacizumab and its biosimilars to reduce drug waste in the oncology care model in a community oncology network. Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, Illinois. Poster 1529.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.